HEALTH CARE:
BIOTECHNOLOGY & LIFE SCIENCES
SIC: BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.
| Market Cap | 2.473 Billion | Shares Outstanding | 32.17 Million | Avg Volume | 137.595 Thousand |
| 1-Yr BETA vs S&P TR | 0.691 | Current Ratio | 2.4 | Quick Ratio | 2.4 |
| Q2 2018 | All Institutions | Hedge Funds 1 |
|---|---|---|
| To trade ARGX now: | |
|
| Filers who had this stock in their top 10: | 4 | 3 (0.29%) |
| 13F Filers holding this stock: | 84 | 32 (3.05%) |
| Aggregate 13F shares on 06/30/2018: | 18.031 Million | 7.946 Million |
| Aggregate 13F shares on 03/31/2018: | 17.003 Million | 7.229 Million |
| Percent change: | 6.05% | 9.91% |
| Funds creating new positions: | 7 | 3 |
| Funds Adding to an existing position: | 40 | 12 |
| Funds closing out their position: | 8 | 2 |
| Funds reducing their position: | 20 | 10 |
| 1 hedge funds as identified by whalewisdom.com through public filings. | ||
Argenx SE ADS Chart by YCharts
Please sign in first
none
none
none
| Reporting Owners | Transaction Date | Transaction Code | Shares | Acquired or Disposed | Shares Owned Following Transaction | Direct/Indirect Ownership |
|---|---|---|---|---|---|---|
| No current insider transactions | ||||||
